false
0001802665
0001802665
2024-10-30
2024-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): October 30, 2024
HARMONY
BIOSCIENCES HOLDINGS, INC.
(Exact name of registrant
as specified in its charter)
| Delaware |
001-39450 |
82-2279923 |
(State or other jurisdiction
of incorporation)
|
(Commission
File Number) |
(IRS Employer
Identification No.) |
630 W. Germantown Pike, Suite 215
Plymouth Meeting, PA 19462
(Address of principal executive offices) (Zip
Code)
(484) 539-9800
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common
Stock, $0.00001 par value per share |
|
HRMY |
|
The
Nasdaq Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On
November 1, 2024, certain shareholders (the “Selling Shareholders”) of Harmony Biosciences Holdings, Inc. (the
“Company”) sold 8,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per
share (“Common Stock”), in a registered public offering pursuant to the Company’s Registration Statement
on Form S-3 ASR (File No. 333-260905) (the “Registration Statement”) filed under the
Securities Act of 1933, as amended, which Registration Statement became automatically effective upon filing on November 9,
2021. The Shares were sold pursuant to an Underwriting Agreement, dated October 30, 2024 (the “Underwriting
Agreement”), among the Company, the Selling Shareholders and J.P. Morgan Securities LLC (the
“Underwriter”). Pursuant to the terms of the Underwriting Agreement, the Selling Shareholders also granted the
Underwriter a 30-day option to purchase up to 1,200,000 additional shares of Common Stock on the same terms (the “Option
Shares”). The Selling Shareholders will receive all of the net proceeds from this offering. The Company will not receive any
of the proceeds from this offering.
The foregoing description of the Underwriting Agreement is not complete
and is qualified in its entirety by the full text of the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1
and is incorporated by reference herein. A copy of the opinion of Latham & Watkins LLP relating to the validity of the Shares
and the Option Shares is filed herewith as Exhibit 5.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
HARMONY BIOSCIENCES HOLDINGS, INC. |
| |
|
| |
|
| Date: November 1, 2024 |
By: |
/s/ Sandip Kapadia |
| |
|
Sandip Kapadia |
| |
|
Chief Financial Officer and Chief Administrative Officer |
Exhibit 1.1
Harmony Biosciences Holdings, Inc.
8,000,000 Shares of Common Stock
Underwriting Agreement
October 30, 2024
J.P. Morgan Securities LLC
As representative
of the several Underwriters
named in Schedule I hereto,
c/o J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Ladies and Gentlemen:
Certain stockholders listed
on Schedule II hereto (the “Selling Stockholders”) of Harmony Biosciences Holdings, Inc., a Delaware corporation (the
“Company”), propose, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell
to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representative (the “Representative”),
an aggregate of 8,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,200,000 additional
shares (the “Optional Shares”) of common stock, par value $0.00001 per share (“Stock”) of the Company (the Firm
Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the
“Shares”). To the extent there are no additional underwriters listed on Schedule I hereto, the term “Representative”
as used herein shall mean you, as Underwriter, and the term “Underwriters” shall mean either the singular or the plural,
as the context requires.
| 1. | Representations and Warranties of the Company
and Each Selling Stockholder |
(a) The
Company represents and warrants to, and agrees with, each of the Underwriters that:
(i) A
registration statement on Form S-3 (File No. 333-260905) (the “Initial Registration Statement”) in respect of the
Shares has been filed with the Securities and Exchange Commission (the “Commission”) not earlier than three years prior to
the date hereof. At (a) the time of filing the Initial Registration Statement, (b) at the time of the most recent amendment
thereto for the purposes of complying with Section 10(a)(3) of the Securities Act of 1933, as amended (the “Act”)
(whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or form of prospectus), and (c) at the time the Company or any
person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Act) made any offer relating
to the Shares in reliance on the exemption of Rule 163 under the Act, the Company was a “well-known seasoned issuer”
as defined in Rule 405 under the Act and the Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under
the Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in
any event prior to the First Time of Delivery. The Initial Registration Statement and any post-effective amendment thereto, each in the
form heretofore delivered to you were effective upon filing pursuant to Rule 462(e) under the Act; no other document with respect
to the Initial Registration Statement has been filed, or transmitted for filing, with the Commission (other than prospectuses filed pursuant
to Rule 424(b) of the rules and regulations of the Commission under the Act, each in the form heretofore delivered to
the Representative); and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment
thereto or any part thereto, has been issued and no proceeding for that purpose has been initiated or, to the Company’s knowledge,
threatened by the Commission. The base prospectus filed as part of the Initial Registration Statement, in the form in which it has most
recently been filed with the Commission on or prior to the date of this Agreement relating to the Shares, is hereinafter called the “Base
Prospectus”; any preliminary prospectus (including any preliminary prospectus supplement) relating to the Shares filed with the
Commission pursuant to Rule 424(b) under the Act is hereinafter called a “Preliminary Prospectus”; the various
parts of the Initial Registration Statement, including all exhibits thereto and including any prospectus supplement relating to the Shares
that is filed with the Commission pursuant to Rule 424(b) under the Act and deemed by virtue of Rule 430B under the Act
to be part of the Initial Registration Statement, each as amended at the time such part of the Initial Registration Statement became
effective, became or hereafter becomes effective, are hereinafter collectively called the “Registration Statement”; the Base
Prospectus, as amended and supplemented immediately prior to the Applicable Time (as defined in Section 1(a)(iii) hereof),
is hereinafter called the “Pricing Prospectus”; the form of the final prospectus (including any final prospectus supplement)
relating to the Shares filed with Commission pursuant to Rule 424(b) under the Act in accordance with Section 5(a)(i) hereof
is hereinafter called the “Prospectus”; any reference herein to the Base Prospectus, the Pricing Prospectus, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item
12 of Form S-3, as of the date of such prospectus; any reference to any amendment or supplement to the Base Prospectus, the Pricing
Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any post-effective amendment to the
Registration Statement, any prospectus supplement relating to the Shares filed with the Commission pursuant to Rule 424(b) under
the Act and any documents filed under the Exchange Act, and incorporated therein, in each case after the date of the Base Prospectus,
such Preliminary Prospectus or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall
be deemed to refer to and include any annual report of the Company filed pursuant to Section 13(a) or 15(d) of the Exchange
Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement; any oral
or written communication with potential investors undertaken in reliance on Rule 163B under the Act is hereinafter called a “Testing-the-Waters
Communication”; and any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under
the Act is hereinafter called a “Written Testing-the-Waters Communication” and any “issuer free writing prospectus”
as defined in Rule 433 under the Act relating to the Shares is hereinafter called an “Issuer Free Writing Prospectus”);
(ii) No
order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission.
Each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the
rules and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements
or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section 9(b) of this Agreement);
(iii) For
the purposes of this Agreement, the “Applicable Time” is 8:00 p.m. (Eastern time) on the date of this Agreement. The
Pricing Prospectus, as supplemented by the information listed on Schedule III(b) hereto, taken together (collectively, the “Pricing
Disclosure Package”), as of the Applicable Time, did not, and as of each Time of Delivery (as defined in Section 4(a) of
this Agreement) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus
and Written Testing-the-Waters Communications does not conflict with the information contained in the Registration Statement, the Pricing
Prospectus or the Prospectus and each Issuer Free Writing Prospectus and Written Testing-the-Waters Communications, as supplemented by
and taken together with the Pricing Disclosure Package, as of the Applicable Time, did not, and as of each Time of Delivery will not,
include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and
warranty shall not apply to statements or omissions made in reliance upon and in conformity with the Underwriter Information;
(iv) The
documents incorporated by reference in the Pricing Prospectus and Prospectus, when they became effective or were filed with the Commission,
as the case may be, conformed in all material respects to the requirements of the Act or the Exchange Act, as applicable, and the rules and
regulations of the Commission thereunder, and none of such documents contained an untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary to make the statements therein not misleading; and any further documents so
filed and incorporated by reference in the Pricing Prospectus and the Prospectus or any further amendment or supplement thereto, when
such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements
of the Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading;
(v) The
Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus
will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder
and do not and will not, as of the applicable effective date as to each part of the Registration Statement, as of the applicable filing
date as to the Prospectus and any amendment or supplement thereto, and as of each Time of Delivery, contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading;
provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in
conformity with the Underwriter Information;
(vi) Neither
the Company nor any of its subsidiaries, taken as a whole, has, since the date of the latest audited financial statements included in
the Pricing Prospectus and the Prospectus, (i) sustained any material loss or material interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order
or decree or (ii) entered into any transaction or agreement (whether or not in the ordinary course of business) that is material
to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material
to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus;
and, since the respective dates as of which information is given in the Registration Statement, the Pricing Prospectus and the Prospectus,
there has not been (x) any change in the capital stock (other than as a result of (i) the exercise, if any, of stock options
or the award, if any, of stock options or restricted stock in the ordinary course of business pursuant to the Company’s equity
plans that are described in the Pricing Prospectus and the Prospectus or (ii) the issuance, if any, of stock upon conversion of
Company securities as described in the Pricing Prospectus and the Prospectus) or long-term debt of the Company or any of its subsidiaries
or (y) any Material Adverse Effect (as defined below); as used in this Agreement, “Material Adverse Effect” shall mean
any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting
(i) the business, properties, general affairs, management, financial position, stockholders' equity, prospects or results of operations
of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus and the Prospectus,
or (ii) the ability of the Company to perform its obligations under this Agreement, including the sale of the Shares, or to consummate
the transactions contemplated in the Pricing Prospectus and the Prospectus;
(vii) The
Company and its subsidiaries have good and marketable title in fee simple to all real property, if any, and good and marketable title
to all material personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are
described in the Pricing Prospectus and the Prospectus or such as do not materially affect the value of such property and do not interfere
with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held
under lease by the Company and its subsidiaries are, held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company
and its subsidiaries;
(viii) Each
of the Company and each of its subsidiaries has been (i) duly organized and is validly existing and in good standing under the laws
of its jurisdiction of organization, with power and authority (corporate and other) to own and/or lease its properties and conduct its
business as described in the Pricing Prospectus and the Prospectus, and (ii) duly qualified as a foreign corporation for the transaction
of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business
so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and each material subsidiary of
the Company has been listed on Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed with the Commission on
February 22, 2024;
(ix) The
Company has an authorized capitalization as set forth in the Pricing Prospectus and the Prospectus and all of the issued shares of capital
stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and conform to the description
of the Stock contained in the Pricing Disclosure Package and the Prospectus; and all of the issued shares of capital stock of each subsidiary
of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and (except, in the case of any foreign
subsidiary, for directors’ qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances,
equities or claims, except for such liens or encumbrances described in the Pricing Prospectus and the Prospectus;
(x) [RESERVED];
(xi) The
compliance by the Company with this Agreement and the consummation of the transactions contemplated in this Agreement and the Pricing
Prospectus and the Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute
a default under, (i) any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company
or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or
assets of the Company or any of its subsidiaries is subject, (ii) the certificate of incorporation or by-laws (or other applicable
organizational document) of the Company or any of its subsidiaries, or (iii) any statute or any judgment, order, rule or regulation
of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties,
except, in the case of clauses (i) or (iii), for such defaults, breaches, or violations that would not, individually or in the aggregate,
have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court
or governmental agency or body is required by the Company for the sale of the Shares by the Selling Stockholders and the consummation
by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the
Financial Industry Regulatory Authority (“FINRA”) of the underwriting terms and arrangements and such consents, approvals,
authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase
and distribution of the Shares by the Underwriters;
(xii) Neither
the Company nor any of its subsidiaries is (i) in violation of its certificate of incorporation or by-laws (or other applicable
organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental
agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, or (iii) in default in
the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust,
loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except,
in the case of the foregoing clauses (ii) and (iii), for such defaults as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect;
(xiii) The
statements set forth in the Pricing Prospectus and the Prospectus under the caption “Description of Capital Stock”, insofar
as they purport to constitute a summary of the terms of the Stock, under the caption “Material U.S. Federal Income Tax Consequences
to Non-U.S. Holders”, and under the caption “Underwriting”, insofar as they purport to describe the provisions of the
laws (other than laws, rules and regulations relating to selling restrictions in various foreign jurisdictions) and documents referred
to therein, are accurate and complete in all material respects;
(xiv) Other
than as set forth in the Pricing Prospectus and the Prospectus, there are no legal or governmental proceedings pending to which the Company
or any of its subsidiaries or, to the Company's knowledge, any officer or director of the Company, is a party or of which any property
of the Company or any of its subsidiaries or, to the Company's knowledge, any officer or director of the Company, is the subject which,
if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in the aggregate
reasonably be expected to have a Material Adverse Effect; and, to the Company's knowledge, no such proceedings are threatened or contemplated
by governmental authorities or others;
(xv) The
Company is not required to be registered as, an “investment company”, as such term is defined in the Investment Company Act
of 1940, as amended;
(xvi) At
the time of filing the Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that
the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the
Shares, and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined under Rule 405 under
the Act;
(xvii) Deloitte &
Touche LLP, who have certified certain financial statements of the Company and its subsidiaries, are independent public accountants as
required by the Act and the rules and regulations of the Commission thereunder;
(xviii) The
Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”) that (i) complies with the applicable requirements
of the Exchange Act, (ii) has been designed by the Company’s principal executive officer and principal financial officer,
or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles, (iii) is sufficient to provide reasonable
assurance that (A) transactions are executed in accordance with management’s general or specific authorization, (B) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and
to maintain accountability for assets, (C) access to assets is permitted only in accordance with management’s general or specific
authorization and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences and (iv) the interactive data in eXtensible Business Reporting Language included
or incorporated by reference in the Registration Statement is accurate; and the Company’s internal control over financial reporting
is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood
that this subsection shall not require the Company to comply with Section 404 of the Sarbanes Oxley Act of 2002, as amended (the
Sarbanes-Oxley Act”) as of an earlier date than it would otherwise be required to so comply under applicable law);
(xix) The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and
guidelines applicable thereto;
(xx) There
is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such,
to comply with any provision of the Sarbanes-Oxley Act, including Section 402 related to loans and Sections 302 and 906 related
to certifications;
(xxi) Since
the date of the latest audited financial statements included in the Pricing Prospectus and the Prospectus, there has been no change in
the Company’s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to
materially and adversely affect, the Company’s internal control over financial reporting;
(xxii) The
Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that
are designed to comply with the applicable requirements of the Exchange Act; such disclosure controls and procedures have been designed
to ensure that material information relating to the Company and its subsidiaries is made known to the Company's principal executive officer
and principal financial officer by others within those entities; and such disclosure controls and procedures are effective;
(xxiii) This
Agreement has been duly authorized, executed and delivered by the Company;
(xxiv) None
of the Company or any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or
other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) made, offered, promised or authorized
any unlawful contribution, gift, entertainment or other unlawful expense; (ii) made, offered, promised or authorized any direct
or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977,
the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law;
(xxv) The
operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable
anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT Act of 2001, and
the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company
and its subsidiaries conduct business (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened;
(xxvi) None
of the Company or any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of
the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. Government,
including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), or the
U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked
person,” the European Union, His Majesty’s Treasury, the United Nations Security Council, or other relevant sanctions authority
(collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or
territory that is the subject or target of Sanctions, and the Company will not directly or indirectly use the proceeds of the offering
of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity (i) to fund or facilitate any activities of or business with any person, or in any country or territory, that,
at the time of such funding, is the subject or the target of Sanctions or (ii) in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
Since April 24, 2019, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in any dealings
or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with
any Sanctioned Country;
(xxvii) The
financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related schedules
and notes, present fairly in all material respects the financial position of the Company and its subsidiaries at the dates indicated
and the statement of operations, stockholders’ equity and cash flows of the Company and its subsidiaries for the periods specified;
said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied
on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in all material respects and
in accordance with GAAP the information required to be stated therein. The financial information included in the Registration Statement,
the Pricing Prospectus and the Prospectus present fairly in all material respects the information shown therein and have been compiled
on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro
forma financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Prospectus
or the Prospectus under the Act or the rules and regulations promulgated thereunder. All disclosures contained in the Registration
Statement, the Pricing Prospectus and the Prospectus regarding “non-GAAP financial measures” (as such term is defined by
the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K
of the Act, to the extent applicable;
(xxviii) Other
than as disclosed in the Prospectus, there are no persons with registration rights or other similar rights to have any securities registered
pursuant to the Registration Statement or otherwise registered by the Company under the Act except as have been validly waived or complied
with in connection with the offering of the Shares;
(xxix) No
labor disturbance by or dispute with current or former employees or officers of the Company or any of its subsidiaries exists or, to
the Company’s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance
by, or dispute with, the employees of any of the Company’s or any of its subsidiaries’ principal suppliers, manufacturers
or contractors. Neither the Company nor any of its subsidiaries is a party to any collective bargaining agreement;
(xxx) The
Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business
interruption insurance, which insurance is in amounts and insures against such losses and risks as are, in the reasonable judgment of
the Company, reasonable and is ordinary and customary for comparable companies in the same or similar businesses; and neither the Company
nor any of its subsidiaries has (i) received written notice from any insurer or agent of such insurer that capital improvements
or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable
cost from similar insurers as may be necessary to continue its business;
(xxxi) The
Company’s board of directors meets the independence requirements of, and has established an audit committee, a compensation committee
and a nominating and corporate governance committee, in each case, that meets the independence requirements of, the rules and regulations
of the Commission and Nasdaq;
(xxxii) The
Company and its subsidiaries, and to the Company’s knowledge, its and their respective directors, officers and employees, are in
compliance with applicable Health Care Laws (defined herein), including, but not limited to, the rules and regulations of the Food
and Drug Administration (“FDA”), the U.S. Department of Health and Human Services Office of Inspector General, the Centers
for Medicare & Medicaid Services, the Office for Civil Rights, and the Department of Justice (with respect to enforcement of
Health Care Laws to which the Company is subject), except for such noncompliance that would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. For purposes of this Agreement, “Health Care Laws” shall mean, as applicable,
the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the
civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Act (42 U.S.C. § 1320a-7b(a)), applicable
criminal laws relating to health care fraud and abuse, the exclusion laws (42 U.S.C. § 1320a-7), the civil monetary penalties law
(42 U.S.C. § 1320a-7a), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. §§ 1320d et seq.),
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. §§ 17921 et seq.) (“HIPAA”),
and the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.). Neither the Company nor any of its subsidiaries is
a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring
agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. Neither the
Company nor any of its subsidiaries has received any written notification, correspondence or any other written or oral communication,
including, without limitation, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other correspondence
or notice from the FDA or any similar regulatory authority, or any notification of any pending or, to the Company’s knowledge,
threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority
of potential or actual material non-compliance by, or material liability of, the Company or its subsidiaries under any Health Care Laws;
(xxxiii) Each
of the Company and its subsidiaries possesses, and is in compliance with the terms of, all applications, certificates, approvals, clearances,
registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate Governmental Authorities
and necessary to conduct their respective businesses (collectively, “Licenses”), including, without limitation, all Licenses
required by the FDA, or any component thereof, and/or by any other U.S., state, local or foreign government or drug regulatory agency
(collectively, the “Regulatory Agencies”), except where a failure to so possess or noncompliance would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. All such Licenses are in full force and effect and neither
the Company nor any of its subsidiaries is in violation of any term or conditions of any such License, except where a failure to be in
full force or effect or such violation would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to such Licenses
and, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in
any other impairment of the rights of the holder of any such License, except for such failure or occurrence that would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received
any written notice of proceedings from the applicable Regulatory Agency proposing to revoke or materially adversely modify any such Licenses
and, to the Company’s knowledge, no Regulatory Agency has taken any action to limit, suspend or revoke any such License possessed
by the Company;
(xxxiv) The
pre-clinical studies and clinical trials conducted or sponsored by or on behalf of the Company, or conducted or sponsored by or on behalf
of a licensor with respect to any products or product candidates licensed by the Company, the results of which are described in the Registration
Statement, the Pricing Prospectus and the Prospectus were and, if still pending, are being, conducted in all material respects in accordance
with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and
regulations; the descriptions of the pre-clinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf
of the Company or by a licensor, and the results thereof, contained in the Registration Statement, the Pricing Prospectus and the Prospectus
are accurate in all material respects; the Company is not aware of any other pre-clinical studies or clinical trials, the results of
which materially call into question the results described in the Registration Statement, the Pricing Prospectus and the Prospectus; and,
except as would not reasonably be expected to have a Material Adverse Effect, the Company has not received any notices or correspondence
from the FDA, any foreign, state or local governmental body exercising comparable authority or any institutional review board or ethics
committee or similar body requiring the termination, suspension, material adverse modification or clinical hold of any pre-clinical studies
or clinical trials currently being conducted or proposed to be conducted: (i) by or on behalf of the Company; or (ii) to the
knowledge of the Company, by or on behalf of a licensor with respect to any products or product candidates licensed by the Company;
(xxxv) Neither
the Company nor its subsidiaries, nor any of its or their respective officers, employees or directors, nor, to the Company’s knowledge,
any of its or their respective agents or clinical investigators, or licensors, has, for the past three (3) years, been excluded,
suspended or debarred from participation in any U.S. federal or foreign health care program or human clinical research or, is subject
to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment,
suspension, or exclusion, or convicted of any crime that would reasonably be expected to result in debarment under 21 U.S.C. § 335a
or comparable foreign law;
(xxxvi) The
Company owns or has valid and enforceable licenses or other rights to all patents and patent applications, copyrights, trademarks, trademark
registrations, service marks, service mark registrations, trade names, service names and know-how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and all other technology and intellectual
property rights necessary for the conduct, or the proposed conduct, of the business of the Company in the manner described in the Pricing
Prospectus and the Prospectus (collectively, the “Company Intellectual Property”); to the Company’s knowledge, there
are no rights of third parties to any of the material patents, trademarks and copyrights within the Company Intellectual Property disclosed
in the Registration Statement and the Prospectus as being owned by the Company and its Subsidiaries and such patents, trademark and copyrights
are owned by the Company free and clear of all material liens, security interests, or encumbrances; to the Company’s knowledge,
the material patents, trademarks and copyrights held or licensed by the Company included within the Company Intellectual Property are
valid, enforceable and subsisting; and other than as disclosed in the Pricing Prospectus and the Prospectus, (i) neither the Company
nor its subsidiaries is obligated to pay a material royalty, grant a material license, or provide other material consideration to any
third party in connection with the Company Intellectual Property, (ii) no action, suit, claim or other proceeding is pending or,
to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in the manner described in the
Pricing Prospectus and the Prospectus is infringing, misappropriating, diluting or otherwise violating any intellectual property rights
of others, (iii) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging
the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv) no action,
suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the Company’s rights
in or to any Company Intellectual Property, (v) to the Company’s knowledge, no third party has any ownership right in or to
any Company Intellectual Property in any field of use that is exclusively licensed to the Company, other than any licensor to the Company
of such Company Intellectual Property, (vi) no employee, consultant or independent contractor of the Company or any of its subsidiaries
is, to the Company’s knowledge, in violation in any material respect of any term of any employment contract, patent disclosure
agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive
covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee’s employment
or independent contractor’s engagement with the Company or actions undertaken while employed or engaged with the Company, (vii) the
Company has taken reasonable measures to protect its material confidential information and material trade secrets and to maintain and
safeguard the material Company Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements,
and (viii) the Company has complied with the material terms of each agreement pursuant to which the Company Intellectual Property
has been licensed to the Company, and all such agreements are in full force and effect; except in each of (i)–(viii) such
as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect;
(xxxvii) All
patents and patent applications within the Company Intellectual Property disclosed in the Registration Statement and the Prospectus as
being owned by the Company and its subsidiaries have, to the knowledge of the Company, been duly and properly filed and maintained; to
the knowledge of the Company, there are no material defects in any of such patents or patent applications; to the knowledge of the Company,
the parties prosecuting such applications have complied with their duty of candor and disclosure to the United States Patent and Trademark
Office (the “USPTO”) in connection with such applications; and the Company is not aware of any facts required to be disclosed
to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application
or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications; except
such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect;
(xxxviii) Any
statistical, industry-related and market-related data included in the Pricing Prospectus and the Prospectus are based on or derived from
sources that the Company believes to be reliable and accurate in all material respects, and, to the extent required, the Company has
obtained the written consent to the use of such data from such sources, if required;
(xxxix) The
Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations
and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities having jurisdiction over the
Company and its subsidiaries that are necessary for the ownership or lease of their respective properties or the conduct of their respective
businesses as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to
possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except
as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries
has received written notice of any revocation or modification of any such license, certificate, permit or authorization, except where
such revocation or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
(xl) All
United States federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed and all taxes
shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except assessments against
which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The Company and its Subsidiaries
have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law
except insofar as the failure to file such returns would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries,
except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been provided and except insofar
as the failure to pay such taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
(xli) Neither
the Company nor any of its subsidiaries has taken and will not take, directly or indirectly, any action that is designed to or that has
constituted or might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares;
(xlii) Neither
the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement)
that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder’s
fee or like payment in connection with the offering and sale of the Shares;
(xliii) No
relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Act to
be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Registration
Statement, the Pricing Disclosure Package and the Prospectus;
(xliv) There
are no contracts, arrangements or documents which are required to be described in the Registration Statement or to be filed as exhibits
thereto which have not been so described and filed as required;
(xlv) The
Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites,
applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects
as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted. To the Company’s
knowledge, its IT Systems are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security
of its IT Systems and certain data (including all personal, personally identifiable, sensitive, confidential or regulated data (“Personal
Data”) used in connection with their businesses, and there have been no actual breaches, violations, outages or unauthorized uses
of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person,
nor any incidents under internal review or investigations relating to the same. Except as would not reasonably be expected to have a
Material Adverse Effect, the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal
Data from unauthorized use, access, misappropriation or modification;
(xlvi) No
forward-looking statement (within the meaning of Section 27A of the Act and Section 21E of the Exchange Act) included or incorporated
by reference in any of the Registration Statement, the Pricing Prospectus or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.
(xlvii) Nothing
has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included
or incorporated by reference in each of the Registration Statement, the Pricing Prospectus and the Prospectus is not based on or derived
from sources that are reliable and accurate in all material respects.
Any certificate signed by any officer
of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the
offering, or the purchase and sale, of the Shares shall be deemed a representation and warranty by the Company to each Underwriter as
to the matters covered thereby.
(b) Each
of the Selling Stockholders severally represents and warrants to each Underwriter and the Company that:
(i) All
consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Stockholder of this Agreement
and the transactions completed herein for the sale and delivery of the Shares to be sold by such Selling Stockholder hereunder, have
been obtained; and such Selling Stockholder has full right, power and authority to enter into this Agreement to sell, assign, transfer
and deliver the Shares to be sold by such Selling Stockholder hereunder; this Agreement has each been duly authorized, executed and delivered
by such Selling Stockholder.
(ii) The
execution, delivery and performance by such Selling Stockholder of this Agreement, the sale of the Shares to be sold by such Selling
Stockholder and the consummation by such Selling Stockholder of the transactions contemplated herein will not (i) conflict with
or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification
or acceleration of, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which such Selling Stockholder
is a party or by which such Selling Stockholder is bound or to which any of the property, right or asset of such Selling Stockholder
is subject, except for such conflicts, breaches, violations or defaults that would not, individually or in the aggregate, reasonably
be expected to impair in any material respect the ability of the Selling Stockholder to perform its obligations under this Agreement,
(ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of such Selling Stockholder,
or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory agency having jurisdiction over the Selling Stockholder or any of its properties.
(iii) Such
Selling Stockholder has, and on the First Time of Delivery and each applicable Second Time of Delivery (as defined below) will have,
good and valid title to, or a valid “security entitlement” within the meaning of Section 8-501 of the New York Uniform
Commercial Code (the “UCC”) to, all of the Shares, free and clear of all security interests, claims, liens, equities or other
encumbrances, subject to sale by such Selling Stockholder pursuant to this Agreement on such date and the legal right and power to sell,
transfer and deliver all of the Shares which may be sold by such Selling Stockholder pursuant to this Agreement and to comply with its
other obligations hereunder. Upon payment for the Shares to be sold by such Selling Stockholder pursuant to this Agreement, delivery
of such Shares, as directed by the Underwriters, to Cede & Co. (“Cede”) or such other nominee as may be designated
by The Depository Trust Company (“DTC”), registration of such Shares in the name of Cede or such other nominee and the crediting
of such Shares on the books of DTC to securities accounts of the Underwriters (assuming that neither DTC nor any such Underwriter has
notice of any adverse claim (within the meaning of Section 8-105 of the UCC) to such Shares), (i) under Section 8-501
of the UCC, the Underwriters will acquire a valid security entitlement in respect of such Shares and (ii) no action based on any
“adverse claim”, within the meaning of Section 8-102 of the UCC, to such Shares may be asserted against the Underwriters
with respect to such security entitlement; for purposes of this representation, such Selling Stockholder may assume that when such payment,
delivery and crediting occur, (x) such Shares will have been registered in the name of Cede or another nominee designated by DTC,
in each case on the Company’s share registry in accordance with its applicable organizational documents, bylaws and applicable
law, (y) DTC will be registered as a “clearing corporation” within the meaning of Section 8-102 of the UCC and
(z) appropriate entries to the accounts of the several Underwriters on the records of DTC will have been made pursuant to the UCC.
(iv) Such
Selling Stockholder has good and valid title to the Shares to be sold at the applicable Time of Delivery by such Selling Stockholder
hereunder, free and clear of all liens, encumbrances, equities or adverse claims; such Selling Stockholder will have, immediately prior
to such applicable Time of Delivery, good and valid title to the Shares to be sold at such Time of Delivery, by such Selling Stockholder,
free and clear of all liens, encumbrances, equities or adverse claims.
(v) Such
Selling Stockholder has not taken and will not take, directly or indirectly, any action designed to or that could reasonably be expected
to cause or result in any stabilization or manipulation of the price of the Shares.
(vi) The
Pricing Disclosure Package, at the Applicable Time did not, and as of applicable time of Time of Delivery, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that this representation and warranty (i) shall
apply only to statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company or
to the Underwriters by such Selling Stockholder specifically for use in connection with the preparation thereof (the “Selling Stockholder
Information”); it being understood that the Selling Stockholder Information shall be limited to the legal name and address of,
and the number of shares beneficially owned and offered by, the Selling Stockholder, and the other information with respect to the Selling
Stockholder that appears under the caption “Selling Shareholders” in the Registration Statement, the Pricing Prospectus or
the Prospectus and (ii) shall not apply to any statements or omissions with respect to Selling Stockholder Information made in reliance
upon and in conformity with the Underwriter Information (as defined in Section 9(b) of this Agreement).
(vii) Other
than the Registration Statement, the Pricing Prospectus and the Prospectus, such Selling Stockholder (including its agents and representatives,
other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any Issuer Free Writing Prospectus or Written Testing-the-Waters Communication, other
than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Act or Rule 134 under
the Act or (ii) the documents listed on Schedule III(a) and Schedule III(c) hereto, each electronic road show and any
other written communications approved in writing in advance by the Company and the Representative.
(viii) As
of the date of the Prospectus and any amendment or supplement thereto and as of such Time of Delivery, the Prospectus will not contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty (i) shall
apply only to statements or omissions made in reliance upon and in conformity with the Selling Stockholder Information and (ii) shall
not apply to any statements or omissions with respect to the Selling Stockholder Information made in reliance upon and in conformity
with the Underwriter Information (as defined in Section 9(b) of this Agreement).
(ix) As
of the date hereof and as of such Time of Delivery that the sale of the Shares by such Selling Stockholder is not and will not be prompted
by any material information concerning the Company which is not set forth in the Registration Statement, the Pricing Disclosure Package
or the Prospectus.
(x) Neither
such Selling Stockholder nor any director, officer or employee of such Selling Stockholder nor, to the knowledge of such Selling Stockholder,
any agent, affiliate or other person associated with or acting on behalf of such Selling Stockholder has (i) made, offered, promised
or authorized any unlawful contribution, gift, entertainment or other unlawful expense; (ii) made, offered, promised or authorized
any direct or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices
Act of 1977, the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law.
(xi) The
operations of such Selling Stockholder are and have been conducted at all times in compliance with applicable Money Laundering Laws and
no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Selling
Stockholder with respect to applicable Money Laundering Laws is pending or, to the knowledge of the Selling Stockholder, threatened.
(xii) Neither
such Selling Stockholder nor any of its subsidiaries, directors, officers or employees, nor, to the knowledge of such Selling Stockholder,
any agent, affiliate or other person associated with or acting on behalf of such Selling Stockholder or any of its subsidiaries is currently
the subject or the target of any Sanctions, nor is the Selling Stockholder located, organized or resident in a country or territory that
is the subject or target of Sanctions, and such Selling Stockholder will not directly or indirectly use the proceeds of the offering
of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity (i) to fund or facilitate any activities of or business with any person, or in any country or territory, that,
at the time of such funding, is the subject or the target of Sanctions or (ii) in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
(xiii) Such
Selling Stockholder has been duly organized and is validly existing and in good standing under the laws of its respective jurisdictions
of organization.
(xiv) Such
Selling Stockholder is not (i) an employee benefit plan subject to Title I of ERISA, (ii) a plan or account subject to Section 4975
of the Code or (iii) an entity deemed to hold “plan assets” of any such plan or account under Section 3(42) of
ERISA, 29 C.F.R. 2510.3-101, or otherwise.
Any certificate signed by (or on behalf
of) such Selling Stockholder and delivered to any Underwriter or to counsel for the Underwriters shall be deemed a representation and
warranty by such Selling Stockholder to each Underwriter as to the matters covered thereby.
| 2. | Subject to the terms and conditions herein
set forth, each Selling Stockholder agrees, severally and not jointly, to sell to each of
the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase
from the Selling Stockholders, at a purchase price per share of $30.3025, from each of the
Selling Stockholders the number of Firm Shares (to be adjusted by you so as to eliminate
fractional shares) determined by multiplying the aggregate number of Firm Shares to be sold
by each of the Selling Stockholders as set forth opposite their respective names in Schedule
I hereto by a fraction, the numerator of which is the aggregate number of Firm Shares to
be purchased by such Underwriter as set forth opposite the name of such Underwriter in Schedule
I hereto and the denominator of which is the aggregate number of Firm Shares to be purchased
by all the Underwriters from all of the Selling Stockholders hereunder. |
In addition, each of the Selling Stockholders
agrees severally and not jointly, as and to the extent indicated in Schedule I hereto, to sell the Optional Shares to the several Underwriters
and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set
forth herein, shall have the option to purchase, severally and not jointly, from each Selling Stockholder the Optional Shares at the
price per share set forth in the previous paragraph less an amount per share equal to any dividends or distributions declared by the
Company and payable on the Underwritten Shares but not payable on the Optional Shares. The Underwriters may exercise the option to purchase
Optional Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus,
by written notice from the Representative to the Selling Stockholders. Such notice shall set forth the aggregate number of Option Shares
as to which the option is being exercised and the date and time when the Optional Shares are to be delivered and paid for, which may
be the same date and time as the Time of Delivery (as defined herein) but shall not be earlier than the First Time of Delivery (as defined
herein) nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date
are postponed in accordance with the provisions of Section 10 hereof). Any such notice shall be given at least two business days
prior to the date and time of delivery specified therein. If any Optional Shares are to be purchased, the number of Optional Shares to
be purchased by each Underwriter shall be the number of Optional Shares which bears the same ratio to the aggregate number of Optional
Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule I hereto (or
such number increased as set forth in Section 12 hereof) bears to the aggregate number of Firm Shares being purchased from the Selling
Stockholders by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representative
in its sole discretion shall make. Any such election to purchase Optional Shares shall be made in proportion to the maximum number of
Optional Shares to be sold by each Selling Stockholder as set forth in Schedule I hereto.
| 3. | Upon the authorization by the Representative
of the release of the Firm Shares, the several Underwriters propose to offer the Firm Shares
for sale upon the terms and conditions set forth in the Pricing Prospectus and the Prospectus. |
| 4. | (a) The Shares to be purchased by each
Underwriter hereunder, in definitive or book-entry form, and in such authorized denominations
and registered in such names as the Representative may request upon at least forty-eight
hours’ prior notice to the Company shall be delivered by or on behalf of the Company
to the Representative, through the facilities of the Depository Trust Company (“DTC”),
for the account of such Underwriter, against payment by or on behalf of such Underwriter
of the purchase price therefor by wire transfer of Federal (same-day) funds to the account
specified by the applicable Selling Stockholder to the Representative at least forty-eight
hours in advance. The Company will cause the certificates, if any, representing the Shares
to be made available for checking and packaging at least twenty-four hours prior to the Time
of Delivery (as defined below) with respect thereto at the office of DTC or its designated
custodian (the “Designated Office”). The time and date of such delivery and payment
shall be, with respect to the Firm Shares, 9:30 a.m., New York City time, on November 1,
2024 or such other time and date as the Representative and the Selling Stockholders may agree
upon in writing, and, with respect to the Optional Shares, 9:30 a.m., New York time, on the
date specified by the Representative in the written notice given by the Representative of
the Underwriters’ election to purchase such Optional Shares, or such other time and
date as the Representative and the Company may agree upon in writing. Such time and date
for delivery of the Firm Shares is herein called the “First Time of Delivery”,
such time and date for delivery of the Optional Shares, if not the First Time of Delivery,
is herein called the “Second Time of Delivery”, and each such time and date for
delivery is herein called a “Time of Delivery”. |
(b) The
Company and each Selling Stockholder acknowledges and agrees that the Representative and the other Underwriters are acting solely in
the capacity of an arm’s length contractual counterparty to the Company and each Selling Stockholder with respect to the offering
of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or
a fiduciary to, or an agent of, the Company, the Selling Stockholders or any other person. Additionally, neither the Representative nor
any other Underwriter is advising the Company, the Selling Stockholders or any other person as to any legal, tax, investment, accounting
or regulatory matters in any jurisdiction. The Company and each Selling Stockholder shall consult with its own advisors concerning such
matters and each shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby,
and neither the Representative nor any other Underwriter shall have any responsibility or liability to the Company or any Selling Stockholder
with respect thereto. Any review by the Representative and the other Underwriters of the Company, the transactions contemplated hereby
or other matters relating to such transactions will be performed solely for the benefit of the Representative and the other Underwriters
and shall not be on behalf of the Company or the Selling Stockholders. Moreover, each Selling Stockholder acknowledges and agrees that,
although the Representative may be required or choose to provide a Selling Stockholder with certain Regulation Best Interest and Form CRS
disclosures in connection with the offering, the Representative and the other Underwriters are not making a recommendation to any Selling
Stockholder to participate in the offering, enter into a “lock-up” agreement, or sell any Shares at the price determined
in the offering, and nothing set forth in such disclosures is intended to suggest that the Representative or any Underwriter is making
such a recommendation.
(c) The
documents to be delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including
the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section 8(k) hereof,
will be delivered at the offices of Paul Hastings LLP, The MetLife Building, 200 Park Avenue, New York, New York, 10166 (the “Closing
Location”), and the Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at
the Closing Location at 5:00 p.m., New York City time, on the New York Business Day next preceding such Time of Delivery, at which meeting
the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto.
For the purposes of this Section 4, “New York Business Day” shall mean each Monday, Tuesday, Wednesday, Thursday and
Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order
to close.
5.
(a) The
Company agrees with each of the Underwriters:
(i) To
prepare the Prospectus in a form approved by the Representative and to file such Prospectus pursuant to Rule 424(b) under the
Act not later than the Commission's close of business on the second business day following the execution and delivery of this Agreement,
or, if applicable, such earlier time as may be required by Rule 430B under the Act; to make no further amendment or any supplement
to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by the Representative promptly
after reasonable notice thereof; to advise the Representative, promptly after it receives notice thereof, of the time when any amendment
to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and
to furnish the Representative with copies thereof; to file promptly all material required to be filed by the Company with the Commission
pursuant to Rule 433(d) under the Act; to advise the Representative, promptly after it receives notice thereof, of the issuance
by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus
in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation
or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration
Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing
or suspending the use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its best
efforts to obtain the withdrawal of such order;
(ii) Promptly
from time to time to take such action as the Representative may reasonably request to qualify the Shares for offering and sale under
the securities laws of such jurisdictions as the Representative may request and to use commercially reasonable efforts to comply with
such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete
the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation
(where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise required);
(iii) Prior
to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement (or such other time as may
be agreed to by the Representative and the Company) and from time to time, to furnish the Underwriters with written and electronic copies
of the Prospectus in New York City in such quantities as the Representative may reasonably request, and, if the delivery of a prospectus
(or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of
nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any event
shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered,
not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order
to comply with the Act, to notify the Representative and upon the Representative’s request to prepare and furnish without charge
to each Underwriter and to any dealer in securities (whose name and address the Underwriters shall furnish to the Company) as many written
and electronic copies as the Representative may from time to time reasonably request of an amended Prospectus or a supplement to the
Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver
a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the
Shares at any time nine months or more after the time of issue of the Prospectus, upon the Representative’s request but at the
expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as the Representative may
request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Act;
(iv) To
make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission’s
Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”)), but in any event not later than sixteen months after
the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the Company
and its subsidiaries (which need not be audited) complying with Section 11(a) of the Act and the rules and regulations
of the Commission thereunder (including, at the option of the Company, Rule 158);
(v) During
the period beginning from the date hereof and continuing to and including the date 60 days after the date of the Prospectus (the “Lock-Up
Period”), not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise
transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Commission a registration statement under
the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options
or warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right
to receive, Stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition
or filing or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is
to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Shares to be sold hereunder or pursuant
to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding
as of, the date of this Agreement), or (iii) publicly disclose the intention to do any of the forgoing, in each case, without the
Representative’s prior written consent; provided, however, that the foregoing restrictions shall not apply to (1) any shares
of Stock or any securities or other awards (including without limitation options, restricted stock or restricted stock units) convertible
into, exercisable for, or that represent the right to receive, shares of Stock pursuant to any stock option plan, incentive plan or stock
purchase plan of the Company (collectively, “Company Stock Plans”) or otherwise in equity compensation arrangements described
in the Registration Statement and the Prospectus, (2) any shares of Stock issued upon the conversion, exercise or exchange of convertible,
exercisable or exchangeable securities outstanding on the date of this Agreement and described in the Registration Statement and the
Prospectus, (3) the filing by the Company of any registration statement on Form S-8 or a successor form thereto relating to
any Company Stock Plan described in the Registration Statement and the Prospectus, (4) any shares of Stock issued to collaborators,
partners, joint ventures or the like pursuant to, and in satisfaction of, any agreement existing as of the date of this Agreement and
described in the Registration Statement and the Prospectus, (5) any shares of Stock or any securities convertible into or exchangeable
for, or that represent the right to receive, shares of Stock issued in connection with any bona fide acquisition, strategic investment,
licensing, commercialization, joint venture, technology transfer or development collaboration agreement with an unaffiliated third party,
so long as the aggregate number of shares of Stock issued or issuable pursuant to this clause and (5) shall not exceed 5% of the
total number of shares of Stock issued and outstanding immediately following the completion of the transactions contemplated by this
Agreement, provided that the recipient of any such shares of Stock or securities issued pursuant to clauses (1), (2), (4) and (5) during
the Lock-Up Period shall enter into an agreement substantially in the form of Annex I hereto;
(vi) If
immediately prior to the third anniversary (the “Renewal Deadline”) of the initial effective date of the Registration Statement,
any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done
so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representative.
If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if
it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representative,
and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline.
The Company will take all other action necessary or appropriate to permit the sale of the Shares to continue as contemplated in the expired
registration statement relating to the Shares. References herein to the Registration Statement shall include such new automatic shelf
registration statement or such new shelf registration statement, as the case may be To furnish to its stockholders as soon as practicable
after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders' equity and cash
flows of the Company and its consolidated subsidiaries certified by independent public accountants) and, as soon as practicable after
the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of
the Registration Statement), to make available to its stockholders consolidated summary financial information of the Company and its
subsidiaries for such quarter in reasonable detail, provided, that no reports, documents or other information needs to be furnished pursuant
to this Section 5(a)(iv) to the extent they are available on EDGAR;
(vii) During
a period of three years from the effective date of the Registration Statement, to furnish to the Representative copies of all reports
or other communications (financial or other) furnished to stockholders, and to deliver to the Representative (i) as soon as they
are available, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange
on which any class of securities of the Company is listed; and (ii) such additional information concerning the business and financial
condition of the Company as the Representative may from time to time reasonably request (such financial statements to be on a consolidated
basis to the extent the accounts of the Company and its subsidiaries are consolidated in reports furnished to its stockholders generally
or to the Commission), provided, that no reports, documents or other information needs to be furnished pursuant to this Section 5(g) to
the extent they are available on EDGAR;
(viii) To
file with the Commission such information on Form 10-Q or Form 10-K as may be required by Rule 463 under the Act; and
(ix) Upon
request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company’s trademarks,
servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the on-line
offering of the Shares (the “License”); provided, however, that the License shall be used solely for the purpose described
above, is granted without any fee and may not be assigned or transferred.
(b) Each
of the Selling Stockholders severally covenants and agrees with each Underwriter that such Selling Stockholder will deliver to the Representative
prior to or at the Closing Date a properly completed and executed United States Treasury Department Form W-9 (or other applicable
form or statement specified by the Treasury Department regulations in lieu thereof) in order to facilitate the Underwriters’ documentation
of their compliance with the reporting and withholding provisions of the Tax Equity and Fiscal Responsibility Act of 1982 with respect
to the transactions herein contemplated.
| 6. | (a) The
Company represents and agrees that, without the prior consent of the Representative, it has
not made and will not make any offer relating to the Shares that would constitute a “free
writing prospectus” as defined in Rule 405 under the Act; each Underwriter represents
and agrees that, without the prior consent of the Company and the Representative, it has
not made and will not make any offer relating to the Shares that would constitute a free
writing prospectus required to be filed with the Commission; any such free writing prospectus
the use of which has been consented to by the Company and the Representative is listed on
Schedule III(a) or Schedule III(b) hereto; |
(b) The
Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus,
including timely filing with the Commission or retention where required and legending; and the Company represents that it has satisfied
and agrees that it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any
electronic road show;
(c) The
Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or Written Testing-the-Waters Communications
any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Testing-the-Waters Communication would conflict
with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue statement of
a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances
then prevailing, not misleading, the Company will give prompt notice thereof to the Representative and, if requested by the Representative,
will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written Testing-the-Waters Communication
or other document which will correct such conflict, statement or omission; provided, however, that the obligations under this Section 6(c) shall
not apply to any statements or omissions in an Issuer Free Writing Prospectus or Testing-the-Waters Communication prepared or authorized
by it made in reliance upon and in conformity with the Underwriter Information (as defined below);
(d) The
Company represents and agrees that (i) it has not engaged in, or authorized any other person to engage in, any Testing-the-Waters
Communications, other than Testing-the-Waters Communication with the prior consent of the Representative with entities that are qualified
institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a) under
the Act; and (ii) it has not distributed, or authorized any other person to distribute, any Testing-the-Waters Communication, other
than those distributed with the prior consent of the Representative that are listed on Schedule III(c) hereto; and the Company reconfirms
that the Underwriters have been authorized to act on its behalf in engaging in Testing-the-Waters Communication; and
(e) Each
Underwriter represents and agrees that (i) any Written Testing-the-Waters Communication undertaken by it were with entities that
are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined
in Rule 501(a) under the Act and (ii) it will not distribute, or authorize any other person to distribute, any Written
Testing-the-Waters Communication, other than those distributed with the prior authorization of Company.
| 7. | The Company covenants and agrees with the several
Underwriters that the Company will pay or cause to be paid the following: (i) the fees,
disbursements and expenses of the Company's counsel and accountants in connection with the
registration of the Shares under the Act and all other expenses incurred in connection with
the preparation, printing, reproduction and filing of the Registration Statement, any Preliminary
Prospectus, any Written Testing-the-Water Communication, any Issuer Free Writing Prospectus
and the Prospectus and amendments and supplements thereto and the mailing and delivering
of copies thereof to the Underwriters and dealers; (ii) the cost of printing or producing
any agreement among Underwriters, this Agreement, the Blue Sky Memorandum, if any, closing
documents (including any compilations thereof) and any other documents in connection with
the offering, purchase, sale and delivery of the Shares; (iii) all expenses incurred
in connection with the qualification of the Shares for offering and sale under state securities
laws as provided in Section 5(a)(ii) hereof, including the documented fees and
disbursements of counsel for the Underwriters in connection with such qualification and in
connection with the Blue Sky survey (iv) the filing fees incident to, and the documented
fees and disbursements of counsel for the Underwriters in connection with, any required review
by FINRA of the terms of the sale of the Shares; (v) the cost of preparing stock certificates;
(vi) the cost and charges of any transfer agent or registrar; and (vii) all other
costs and expenses incident to the performance of its obligations hereunder which are not
otherwise specifically provided for in this Section. It is understood, however, that the
amount payable by the Company pursuant to subsections (iii) and (v) for the fees
and disbursements of counsel to Underwriters shall not exceed $30,000 in the aggregate. It
is understood, however, that, except as provided in this Section 7, and Sections 9 and
12 hereof, (i) the Underwriters will pay all of their own costs and expenses, including
the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and
any advertising expenses connected with any offers they may make, (ii) the Company will
bear all of the Company’s (but not the Underwriters’) travel expenses and the
Underwriters will bear all of the Underwriters’ (but not the Company’s) travel
expenses, in each case, in connection with any “roadshow” presentation to investors
and (iii) notwithstanding clause (ii), the Company, on the one hand, and the Underwriters,
on the other hand, shall each pay 50% of the cost of any chartered plane, chartered jet or
other chartered aircraft that is used to transport representatives from both the Company
and the Underwriters in connection with any “roadshow” presentation to investors. |
| 8. | The obligations of the Underwriters hereunder,
as to the Shares to be delivered at each Time of Delivery, shall be subject, in their discretion,
to the condition that all representations and warranties and other statements of the Company
and each Selling Stockholder herein are, at and as of the Applicable Time and such Time of
Delivery, true and correct, the condition that the Company and each Selling Stockholder shall
have performed all of their respective obligations hereunder theretofore to be performed,
and the following additional conditions: |
(a) The
Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period
prescribed for such filing by the rules and regulations under the Act and in accordance with Section 5(a) hereof and in
any event prior to the First Time of Delivery; all material required to be filed by the Company pursuant to Rule 433(d) under
the Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433; no stop
order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that
purpose shall have been initiated or threatened by the Commission; no stop order suspending or preventing the use of the Pricing Prospectus,
Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional
information on the part of the Commission shall have been complied with to the Representative’s reasonable satisfaction;
(b) Paul
Hastings LLP, counsel for the Underwriters, shall have furnished to the Representative their written opinion and negative assurance letter,
dated such Time of Delivery, in form and substance satisfactory to the Representative, and such counsel shall have received such papers
and information as they may reasonably request to enable them to pass upon such matters;
(c) Latham &
Watkins LLP, counsel for the Company, shall have furnished to the Representative their written opinion and negative assurance letter,
dated such Time of Delivery, in form and substance satisfactory to the Representative;
(d) Hogan
Lovells LLP, intellectual property counsel for the Company shall have furnished to the Representative their written opinion dated such
Time of Delivery, in form and substance satisfactory to the Representative;
(e) Vedder
Price P.C., counsel to each of the Selling Stockholders shall have furnished to the Representative their written opinion dated such Time
of Delivery, in form and substance satisfactory to the Representative.
(f) On
the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New York City time, on the effective date
of any post-effective amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of
Delivery, Deloitte & Touche LLP shall have furnished to the Representative a letter or letters, dated the respective dates of
delivery thereof, in form and substance satisfactory to the Representative;
(g) Neither
the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included in the
Pricing Prospectus and the Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether
or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth
or contemplated in the Pricing Prospectus and the Prospectus, and (ii) since the respective dates as of which information is given
in the Pricing Prospectus and the Prospectus there shall not have been any change in the capital stock (other than as a result of the
exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company’s
equity plans that are described in the Pricing Prospectus and the Prospectus) or long-term debt of the Company or any of its subsidiaries
or any change or effect, or any development involving a prospective change or effect, in or affecting (x) the business, properties,
general affairs, management, financial position, stockholders' equity, prospects or results of operations of the Company and its subsidiaries,
taken as a whole, except as set forth or contemplated in the Pricing Prospectus and the Prospectus, or (y) the ability of the Company
to perform its obligations under this Agreement, including the sale of the Shares, or to consummate the transactions contemplated in
the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in the Representative’s
judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the
Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;
(h) On
or after the Applicable Time there shall not have occurred any of the following: (i) a suspension or material limitation in trading
in securities generally on Nasdaq or the New York Stock Exchange; (ii) a suspension or material limitation in trading in the Company’s
securities on Nasdaq; (iii) a general moratorium on commercial banking activities declared by either Federal or New York State authorities
or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv) the outbreak
or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v) the
occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere,
if the effect of any such event specified in clause (iv) or (v) in the Representative’s judgment makes it impracticable
or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms
and in the manner contemplated in the Pricing Prospectus and the Prospectus;
(i) The
Company shall have obtained and delivered to the Underwriters executed copies of an agreement from each director, officer and security
holder of the Company set forth on Schedule IV hereto, substantially to the effect set forth in Annex I hereto in form and substance
satisfactory to the Representative;
(j) The
Company shall have complied with the provisions of Section 5(a)(iii) hereof with respect to the furnishing of prospectuses
on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by the Representative
and the Company); and
(k) The
Company and each Selling Stockholder shall have furnished or caused to be furnished to the Representative at such Time of Delivery certificates
of officers of the Company or officers, trustees or other authorized persons of the applicable Selling Stockholder satisfactory to the
Representative as to the accuracy of the representations and warranties of the Company and each Selling Stockholder, as applicable, herein
at and as of such Time of Delivery, as to the performance by the Company and such Selling Stockholder of all of their respective obligations
hereunder to be performed at or prior to such Time of Delivery, as to the matters set forth in subsections (a) and (g) of this
Section and as to such other matters as the Representative may reasonably request.
| 9. | (a) The Company will indemnify and hold
harmless each Underwriter against any losses, claims, damages or liabilities, joint or several,
to which such Underwriter may become subject, under the Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon an untrue statement or alleged untrue statement of a material fact contained in
the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus,
or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any “roadshow”
as defined in Rule 433(h) under the Act (a “roadshow”), any “issuer
information” filed or required to be filed pursuant to Rule 433(d) under
the Act or any Written Testing-the-Water Communication, or arise out of or are based upon
the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, and will reimburse each Underwriter
for any legal or other expenses reasonably incurred by such Underwriter in connection with
investigating or defending any such action or claim as such expenses are incurred; provided,
however, that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage or liability arises out of or is based upon an untrue statement
or alleged untrue statement or omission or alleged omission made in the Registration Statement,
any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or
supplement thereto, or any Issuer Free Writing Prospectus, any roadshow, or any Written Testing-the-Water
Communication, in reliance upon and in conformity with the Underwriter Information. |
(b) Each
Underwriter, severally and not jointly, will indemnify and hold harmless the Company and each Selling Stockholder against any losses,
claims, damages or liabilities to which the they may become subject, under the Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment
or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Testing-the-Water Communication, or arise out of
or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus
or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Testing-the-Water
Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company or the Selling Stockholder,
as applicable, for any legal or other expenses reasonably incurred by such party in connection with investigating or defending any such
action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, “Underwriter
Information” shall mean the written information furnished to the Company by such Underwriter through the Representative expressly
for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following
information in the Prospectus furnished on behalf of each Underwriter: the information contained in the third, seventh and fifteenth
paragraphs under the caption “Underwriting”.
(c) Each
of the Selling Stockholders severally in proportion to the number of Shares to be sold by such Selling Stockholder hereunder agrees to
indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to which such Underwriter
may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing
Prospectus, any “roadshow” as defined in Rule 433(h) under the Act (a “roadshow”), any “issuer
information” filed or required to be filed pursuant to Rule 433(d) under the Act or any Testing-the-Water Communication,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, but only to the extent, that such untrue statement or alleged untrue statement
or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus,
or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, any roadshow, or any Testing-the-Water Communication in
reliance upon and in conformity with the Selling Stockholder Information relating to such Selling Stockholder; and will reimburse
each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending
any such action or claim as such expenses are incurred; provided, however, such Selling Stockholder shall not be liable in any such case
to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement
or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus,
or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, any roadshow, or any Testing-the-Water Communication,
in reliance upon and in conformity with the Underwriter Information, and provided, further, that the liability under this subsection
(c) of such Selling Stockholder shall be limited to an amount equal to the aggregate gross proceeds after underwriting commissions
and discounts, but before expenses, to such Selling Stockholder from the sale of the Shares sold by such Selling Stockholder hereunder.
(d) Promptly
after receipt by an indemnified party under subsection (a), (b) or (c) of this Section 9 of notice of the commencement
of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection,
notify the indemnifying party in writing of the commencement thereof; provided that the failure to notify the indemnifying party shall
not relieve it from any liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it
has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that
the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise
than under the preceding paragraphs of this Section 9. In case any such action shall be brought against any indemnified party and
it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and,
to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel
reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the
indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel
or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than
reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement
or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such
action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from
all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act, by or on behalf of any indemnified party.
(e) If
the indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under
subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred
to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such
losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Selling Stockholders on the one hand and the Underwriters on the other from the offering of the Shares.
If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying
party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only
such relative benefits but also the relative fault of the Company and the Selling Stockholders on the one hand and the Underwriters on
the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in
respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling
Stockholders on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds
from the offering (before deducting expenses) received by the Selling Stockholders bear to the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission
or alleged omission to state a material fact relates to information supplied by the Company and/or the Selling Stockholders on the one
hand or the Underwriters on the other and the parties' relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Company, the Selling Stockholders and the Underwriters agree that it would not be just and equitable
if contribution pursuant to this subsection (e) were determined by pro rata allocation (even if the Underwriters were treated
as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred
to above in this subsection (e). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities
(or actions in respect thereof) referred to above in this subsection (e) shall be deemed to include any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding
the provisions of this subsection (e), no Underwriter shall be required to contribute any amount in excess of the amount by which the
total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any
damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or
alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters' obligations in this
subsection (e) to contribute are several in proportion to their respective underwriting obligations and not joint.
(f) The
obligations of the Company and the Selling Stockholders under this Section 9 shall be in addition to any liability which they may
otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each
person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any Underwriter;
and the obligations of the Underwriters under this Section 9 shall be in addition to any liability which the respective Underwriters
may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company and the Selling
Stockholders, and to each person, if any, who controls the Company and any Selling Stockholder within the meaning of the Act.
(g) The
remedies provided for in this Section 9 paragraphs (a) through (f) are not exclusive and shall not limit any rights or
remedies which may otherwise be available to any indemnified party at law or in equity.
| 10. | (a) If any Underwriter shall default
in its obligation to purchase the Shares which it has agreed to purchase hereunder at a Time
of Delivery, the Representative may in the Representative’s discretion arrange for
the Representative or another party or other parties to purchase such Shares on the terms
contained herein. If within thirty-six hours after such default by any Underwriter the Representative
does not arrange for the purchase of such Shares, then the Company shall be entitled to a
further period of thirty-six hours within which to procure another party or other parties
satisfactory to the Representative to purchase such Shares on such terms. In the event that,
within the respective prescribed periods, the Representative notifies the Company and the
Selling Stockholders that the Representative has so arranged for the purchase of such Shares,
or the Company or the Selling Stockholders notify the Representative that it has so arranged
for the purchase of such Shares, the Representative, the Company or Selling Stockholders
shall have the right to postpone such Time of Delivery for a period of not more than five
days, in order to effect whatever changes may thereby be made necessary in the Registration
Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees
to file promptly any amendments or supplements to the Registration Statement or the Prospectus
which in the Representative’s opinion may thereby be made necessary. The term “Underwriter”
as used in this Agreement shall include any person substituted under this Section with
like effect as if such person had originally been a party to this Agreement with respect
to such Shares. |
(b) If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the Representative,
the Company and the Selling Stockholders as provided in subsection (a) above, the aggregate number of such Shares which remains
unpurchased does not exceed one-eleventh of the aggregate number of all the Shares to be purchased at such Time of Delivery, then the
Selling Stockholders shall have the right to require each non-defaulting Underwriter to purchase the number of Shares which such Underwriter
agreed to purchase hereunder at such Time of Delivery and, in addition, to require each non-defaulting Underwriter to purchase its pro
rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter
or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability
for its default.
(c) If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the Representative,
the Company and the Selling Stockholders as provided in subsection (a) above, the aggregate number of such Shares which remains
unpurchased exceeds one-eleventh of the aggregate number of all the Shares to be purchased at such Time of Delivery, or if the Selling
Stockholders shall not exercise their right described in subsection (b) above to require non-defaulting Underwriters to purchase
Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery, the obligations
of the Underwriters to purchase and of the Selling Stockholders to sell the Optional Shares) shall thereupon terminate, without liability
on the part of any non-defaulting Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters
as provided in Section 7 hereof and the indemnity and contribution agreements in Section 9 hereof; but nothing herein shall
relieve a defaulting Underwriter from liability for its default.
| 11. | The respective indemnities, rights of contribution,
agreements, representations, warranties and other statements of the Company, the Selling
Stockholders and the several Underwriters, as set forth in this Agreement or made by or on
behalf of them, respectively, pursuant to this Agreement, shall remain in full force and
effect, regardless of any investigation (or any statement as to the results thereof) made
by or on behalf of any Underwriter or any controlling person of any Underwriter or the Selling
Stockholders or the Company, or any officer or director or controlling person of such party,
and shall survive delivery of and payment for the Shares. |
| 12. | If this Agreement shall be terminated pursuant
to Section 10 hereof, the Company and the Selling Stockholders shall not then be under
any liability to any Underwriter except as provided in Sections 7 and 9 hereof; but,
if for any other reason, any Shares are not delivered by or on behalf of the Selling Stockholders
as provided herein, the Company will reimburse the Underwriters through the Representative
for all out-of-pocket expenses approved in writing by the Representative, including fees
and disbursements of counsel, reasonably incurred by the Underwriters in making preparations
for the purchase, sale and delivery of the Shares not so delivered, but the Company shall
then be under no further liability to any Underwriter except as provided in Sections 7 and
9 hereof. |
| 13. | In all dealings hereunder, the Representative
shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled
to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter
made or given by the Representative on behalf of the Underwriters. |
All statements, requests,
notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile
transmission to the Representative in care of J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358);
Attention: Equity Syndicate Desk; if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address
of the Company set forth in the Registration Statement, Attention: Secretary; and if to the Selling Stockholders the address of such
Selling Stockholder appearing in Schedule II. Any such statements, requests, notices or agreements shall take effect upon receipt thereof.
In accordance with the requirements
of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain,
verify and record information that identifies their respective clients, including the Company and the Selling Stockholders, which information
may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly
identify their respective clients.
| 14. | This Agreement shall be binding upon, and
inure solely to the benefit of, the Underwriters, the Company and, to the extent provided
in Sections 9 and 11 hereof, the officers and directors of the Company and each person who
controls the Company, the Selling Stockholders, or any Underwriter, and their respective
heirs, executors, administrators, successors and assigns, and no other person shall acquire
or have any right under or by virtue of this Agreement. No purchaser of any of the Shares
from any Underwriter shall be deemed a successor or assign by reason merely of such purchase. |
| 15. | Time shall be of the essence of this Agreement.
As used herein, the term “business day” shall mean any day when the Commission's
office in Washington, D.C. is open for business. |
| 16. | This Agreement supersedes all prior agreements
and understandings (whether written or oral) between the Company and the Underwriters, or
any of them, with respect to the subject matter hereof. |
| 17. | This Agreement and any transaction contemplated
by this Agreement shall be governed by and construed in accordance with the laws of the State
of New York without regard to principles of conflict of laws that would results in the application
of any other law than the laws of the State of New York. The Company agrees that any suit
or proceeding arising in respect of this Agreement or any transaction contemplated by this
Agreement will be tried exclusively in the U.S. District Court for the Southern District
of New York or, if that court does not have subject matter jurisdiction, in any state court
located in The City and County of New York and the Company agrees to submit to the jurisdiction
of, and to venue in, such courts. |
| 18. | The Company, each Selling Stockholder and
each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby. |
| 19. | This Agreement may be executed by any one
or more of the parties hereto in any number of counterparts, each of which shall be deemed
to be an original, but all such counterparts shall together constitute one and the same instrument. |
| 20. | Notwithstanding
anything herein to the contrary, the Company and each Selling Stockholder is authorized to
disclose to any persons the U.S. federal and state income tax treatment and tax structure
of the potential transaction and all materials of any kind (including tax opinions and other
tax analyses) provided to the Company and the Selling Stockholder relating to that treatment
and structure, without the Underwriters imposing any limitation of any kind. However, any
information relating to the tax treatment and tax structure shall remain confidential (and
the foregoing sentence shall not apply) to the extent necessary to enable any person to comply
with securities laws. For this purpose, “tax structure” is limited to any facts
that may be relevant to that treatment. |
| 21. | Recognition of the U.S. Special Resolution
Regimes. |
| 22. | In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under
a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and
any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a
state of the United States. |
| 23. | In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter
becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under
this Agreement that may be exercised against such Underwriter are permitted to be exercised
to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution
Regime if this Agreement were governed by the laws of the United States or a state of the
United States. |
| 24. | As used in this section: |
“BHC Act Affiliate”
has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).
(a) “Covered
Entity” means any of the following:
(i) a
“covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a
“covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii) a
“covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
“Default Right”
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1,
as applicable.
“U.S. Special Resolution
Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
If the foregoing is in accordance with your understanding,
please sign and return to us counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this
letter and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood
that your acceptance of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement
among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part
as to the authority of the signers thereof.
| |
Very truly yours, |
| |
|
|
| |
Harmony Biosciences Holdings, Inc., |
| |
|
|
| |
By: |
/s/ Christian Ulrich |
| |
|
Name: Christian Ulrich |
| |
|
Title General Counsel &
Corporate Secretary |
| |
|
|
| |
|
|
| |
Marshman Fund Trust II |
| |
|
|
| |
By: |
/s/ Charles Harris |
| |
|
Name: Charles Harris |
| |
|
Title: Co-Trustee |
| |
|
|
| |
|
|
| |
Valor IV Pharma Holdings, LLC |
| |
|
|
| |
By: |
/s/ Antonio J. Gracias |
| |
|
Name: Antonio J. Gracias |
| |
|
Title: Sole
Manager |
Accepted as of the date hereof:
J.P. Morgan Securities LLC
| By: |
/s/ David Ke |
|
| |
Name: David Ke |
|
| |
Title: Managing Director |
|
On behalf of each of the Underwriters
[Signature Page to Underwriting Agreement]
SCHEDULE I
| | |
| | |
Total Number of Optional | |
| | |
| | |
Shares to be | |
| | |
Total Number of | | |
Purchased if | |
| | |
Firm Shares | | |
Maximum Option | |
| Underwriter | |
to be Purchased | | |
Exercised | |
| J.P. Morgan Securities LLC | |
| 8,000,000 | | |
| 1,200,000 | |
| | |
| | | |
| | |
| Total | |
| 8,000,000 | | |
| 1,200,000 | |
SCHEDULE II
| Selling Stockholder | |
| |
| | |
Optional
Shares to
be Sold | |
Marshman
Fund Trust II
| |
[***] | |
| 4,000,000 | | |
| 600,000 | |
| Valor IV Pharma
Holdings, LLC | |
[***] | |
| 4,000,000 | | |
| 600,000 | |
SCHEDULE III
(a) Issuer Free Writing Prospectuses not
included in the Pricing Disclosure Package:
None.
(b) Information other than the Pricing Prospectus
that comprise the Pricing Disclosure Package:
The initial public offering
price per share for the Shares is $31.00
The number of Shares purchased
by the Underwriter is 8,000,000
(c) Written Testing-the-Waters Communications:
None.
SCHEDULE IV
ANNEX I
FORM OF LOCK-UP AGREEMENT
Harmony Biosciences Holdings, Inc.
Lock-Up Agreement
,
2024
J.P Morgan Securities LLC
As representative of the several Underwriters
c/o J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Re: Harmony Biosciences
Holdings, Inc. – Lock-Up Agreement
Ladies and Gentlemen:
The undersigned, currently
an owner of equity interests in Harmony Biosciences Holdings, Inc., a Delaware corporation (the “Company”), understands
that you, as representative (the “Representative”), propose to enter into an Underwriting Agreement on behalf of the several
Underwriters named in Schedule I to such agreement (collectively, the “Underwriters”), with the Company and the selling stockholders
named therein (the “Selling Stockholders”), providing for a public offering of shares (the “Shares”) of common
stock of the Company, par value $0.00001 (the “Common Stock”), by the Selling Stockholders (the “Offering”).
In consideration of the agreement
by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is
hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this Lock-Up Agreement and continuing
to and including the date [60/90] days after the date set forth on the final prospectus supplement used to sell the Shares (the “Lock-Up
Period”), the undersigned will not offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or
otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of Common Stock of
the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the
Company, whether now owned or hereinafter acquired, owned directly by the undersigned (including holding as a custodian) or with respect
to which the undersigned has beneficial ownership within the rules and regulations of the Securities and Exchange Commission (the
“SEC”) (collectively the “Undersigned’s Shares”). The foregoing restriction is expressly agreed to preclude
the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead
to or result in a sale or disposition of the Undersigned’s Shares even if such Shares would be disposed of by someone other than
the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale
or grant of any right (including without limitation any put or call option) with respect to any of the Undersigned’s Shares or
with respect to any security that includes, relates to, or derives any significant part of its value from such Shares.
Notwithstanding the foregoing,
the undersigned may transfer the Undersigned’s Shares:
(i) as
a bona fide gift or gifts or by will or intestacy upon the death of the undersigned; provided that the donee or donees, beneficiary
or beneficiaries, heir or heirs or legal representatives thereof agree to be bound in writing by the restrictions set forth herein, and
provided further that, in the case of any such transfer pursuant to this clause (i), if the undersigned is required to file a
report under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) in connection with such transfer, the undersigned
shall include a statement in such report to the effect that the filing relates to the transfer of securities by bona fide gift or gifts
or by will or intestacy;
(ii) to
any trust, partnership or limited liability company for the direct or indirect benefit of the undersigned or the immediate family of
the undersigned; provided that the trustee of the trust or the partnership or limited liability company agrees to be bound in
writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for
value;
(iii) to
any direct or indirect wholly owned subsidiary, limited partners, members, stockholders, other equity holders or trust beneficiaries
of the undersigned or, if the undersigned is a trust, to a trustee of the undersigned, or to any investment fund or other entity controlled
or managed by or under common control or management with the undersigned, provided that the transferee agrees to be bound in writing
by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value;
(iv) to
a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iii) above;
provided that the transferee agrees to be bound in writing by the restrictions set forth herein;
(v) pursuant
to an order of a court or regulatory agency or to comply with any regulations related to the undersigned’s ownership of the Shares;
provided that, if the undersigned is required to file a report under the Exchange Act in connection with such transfer, the undersigned
shall include a statement in such report to the effect that the filing relates to the transfer of securities pursuant to an order of
a court or regulatory agency or to comply with any regulations related to the ownership of the Shares unless such a statement would be
prohibited by any applicable law, regulation or order of a court or regulatory authority;
(vi) to
the Company as the result of a vesting, conversion, exercise or exchange of any security convertible into or exercisable or exchangeable
for shares of Common Stock pursuant to any existing employee benefit plans described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus (in each case, as defined in the Underwriting Agreement), including shares of Common Stock surrendered or
transferred to the Company in connection with a “cashless” or “net exercise” to cover tax withholding obligations
of the undersigned in connection with such vesting, conversion, exercise or exchange; provided that any shares of Common Stock
received upon such conversion, exercise or exchange shall be subject to the restrictions set forth herein; and provided further
that, if the undersigned is required to file a report under the Exchange Act in connection with such transfer, the undersigned shall
include a statement in such report to the effect that the filing relates to the conversion, exercise or exchange of securities convertible
into or exercisable or exchangeable for shares of Common Stock pursuant to existing employee benefit plans;
(vii) pursuant
to a change of control (as defined below) of the Company that has been approved by the Company’s board of directors; provided
that in the event that the change of control is not completed, the Undersigned’s Shares that are subject to the restrictions
contained in this Lock-Up Agreement shall remain so restricted in accordance with this Lock-Up Agreement;
(viii) in
transactions pursuant to any trading plan pursuant to Rule 10b5-1 (a “10b5-1 Plan”) under the Exchange Act, entered
into prior to the date hereof; provided that, in the case of any such transaction pursuant to this clause (viii), if the undersigned
is required to file a report under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) in connection with
such transfer, the undersigned shall include a statement in such report to the effect that the filing relates to the sale of securities
pursuant to a 10b5-1 Plan;
(ix) that
were acquired in the Offering or in open market transactions following the date of the Underwriting Agreement; or
(x) with the prior written consent of the Representative on behalf of the Underwriters.
In addition, with respect to clauses (i), (ii),
(iii), (iv), (v), (vi), (viii) and (ix) above, it shall be a condition to such transfer that no filing under Section 16(a) of
the Exchange Act reporting a reduction in beneficial ownership (other than a Form 5 the filing deadline for which falls during the
Lock-Up Period) shall be required or voluntarily made during the Lock-Up Period, except as contemplated by clauses (i), (v), (vi) and
(viii) above.
For purposes of this Lock-Up Agreement, (i) “immediate
family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin and (ii) “change
of control” shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction
the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons,
becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of the voting capital stock
of the Company.
The undersigned now has except as contemplated
by clause (ix) above, and, except as contemplated by clauses (i) through (ix) above, for the duration of this Lock-Up
Agreement will have, good and marketable title to the Undersigned’s Shares, free and clear of all liens, encumbrances, and claims
whatsoever. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent
and registrar against the transfer of the Undersigned’s Shares except in compliance with the foregoing restrictions.
Nothing in this Lock-Up Agreement shall prevent
the establishment by the undersigned of any contract, instruction or plan (a “Plan”) that satisfies all of the requirements
of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act; provided, that it shall be a condition to the establishment of any
such Plan that no sales of Common Stock shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period; and provided
further, no voluntary disclosure of such Plan be made by the undersigned prior to the expiration of the Lock-Up Period and any required
public disclosure of such plan includes the restrictions set forth in this Lock-Up Agreement.
The undersigned understands that the Company
and the Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the Offering. The undersigned further
understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives,
successors, and assigns.
The undersigned acknowledges and agrees that
the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned
with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to
the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required or choose
to provide certain Regulation Best Interest and Form CRS disclosures to the undersigned in connection with the Offering, the Representative
and the other Underwriters are not making a recommendation to the undersigned to participate in the Offering, enter into this Lock-Up
Agreement, or sell any Shares at the price determined in the Offering, and nothing set forth in such disclosures is intended to suggest
that the Representative or any Underwriter is making such a recommendation.
This Lock-Up Agreement shall automatically terminate
and be of no further force and effect upon the earlier to occur of: (i) the Company or the undersigned (if the undersigned is a
Selling Stockholder) advising the Underwriters in writing prior to the execution of the Underwriting Agreement that it does not intend
to proceed with the Offering; (ii) the termination of the Underwriting Agreement before the closing of the Offering; (iii) the
registration statement for the Offering is withdrawn; or (iv) November 7, 2024, if the Underwriting has not been executed by
that date.
| |
Very truly yours, |
| |
|
|
| |
|
|
| |
By: |
|
| |
|
Name: |
| |
|
Title: |
Exhibit 5.1
| |
330 North Wabash Avenue
Suite 2800
Chicago, Illinois 60611
Tel: +1.312.876.7700 Fax: +1.312.993.9767
www.lw.com
|
 |
|
|
| |
FIRM / AFFILIATE OFFICES |
| |
Austin |
Milan |
| |
Beijing |
Munich |
| |
Boston |
New York |
| |
Brussels |
Orange County |
| |
Century City |
Paris |
| |
Chicago |
Riyadh |
| |
Dubai |
San Diego |
| November 1, 2024 |
Düsseldorf |
San Francisco |
|
Frankfurt |
Seoul |
|
Hamburg |
Silicon Valley |
| |
Hong Kong |
Singapore |
| Harmony Biosciences Holdings, Inc. |
Houston |
Tel Aviv |
| 630 W. Germantown Pike, Suite 215 |
London |
Tokyo |
| Plymouth Meeting, PA 19462 |
Los Angeles |
Washington, D.C. |
| |
Madrid |
|
| Re: | Registration Statement
No. 333-260905
9,200,000 Shares of
Common Stock |
To the addressees set forth above:
We
have acted as special counsel to Harmony Biosciences Holdings, Inc., a Delaware corporation (the “Company”),
in connection with the proposed sale by certain shareholders of the Company (the “Selling Shareholders”) of
up to 9,200,000 shares of the Company’s common stock, par value $0.00001 per share (the “Shares”).
The Shares are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”),
filed with the Securities and Exchange Commission (the “Commission”) on November 9, 2021 (Registration
No. 333-260905) (as so filed and as amended, the “Registration Statement”), a base prospectus, dated November 9,
2021, included in the Registration Statement at the time it originally became effective (the “Base Prospectus”),
a preliminary prospectus supplement dated October 29, 2024, filed with the Commission pursuant to Rule 424(b) under the
Act (together with the Base Prospectus, the “Preliminary Prospectus”), and a final prospectus supplement, dated
October 30, 2024, filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus,
the “Prospectus”), and are being offered pursuant to an underwriting agreement, dated October 30, 2024
(the “Underwriting Agreement”), among the Company, the Selling Shareholders and the underwriter named therein.
This opinion is being furnished in connection
with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining
to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the sale of
the Shares.
As such counsel, we have examined such matters
of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates
and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.
We are opining herein as to the internal laws of the Delaware General Corporation Law (the “DGCL”), and we
express no opinion with respect to any other laws.
Subject to the foregoing and the other matters
set forth herein, it is our opinion that, as of the date hereof, the Shares have been duly authorized by all necessary corporate action
of the Company and are validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company
will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.
This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company’s
Current Report on Form 8-K, dated November 1, 2024, and to the reference to our firm in the Prospectus under the heading
“Legal Matters.” In giving such consent, we do not thereby admit that we are in the category of persons whose consent is
required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
| |
Sincerely, |
| |
|
| |
/s/ Latham & Watkins LLP |
v3.24.3
Cover
|
Oct. 30, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Oct. 30, 2024
|
| Entity File Number |
001-39450
|
| Entity Registrant Name |
HARMONY
BIOSCIENCES HOLDINGS, INC.
|
| Entity Central Index Key |
0001802665
|
| Entity Tax Identification Number |
82-2279923
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
630 W. Germantown Pike
|
| Entity Address, Address Line Two |
Suite 215
|
| Entity Address, City or Town |
Plymouth Meeting
|
| Entity Address, State or Province |
PA
|
| Entity Address, Postal Zip Code |
19462
|
| City Area Code |
484
|
| Local Phone Number |
539-9800
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, $0.00001 par value per share
|
| Trading Symbol |
HRMY
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Harmony Biosciences (NASDAQ:HRMY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Harmony Biosciences (NASDAQ:HRMY)
Historical Stock Chart
From Nov 2023 to Nov 2024
